<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Environ Res</journal-id><journal-id journal-id-type="iso-abbrev">Environ. Res</journal-id><journal-title-group><journal-title>Environmental Research</journal-title></journal-title-group><issn pub-type="ppub">0013-9351</issn><issn pub-type="epub">1096-0953</issn><publisher><publisher-name>Elsevier Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7406431</article-id><article-id pub-id-type="publisher-id">S0013-9351(20)30914-2</article-id><article-id pub-id-type="doi">10.1016/j.envres.2020.110017</article-id><article-id pub-id-type="publisher-id">110017</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Hispolon: A natural polyphenol and emerging cancer killer by multiple cellular signaling pathways</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Sarfraz</surname><given-names>Ayesha</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Rasul</surname><given-names>Azhar</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Sarfraz</surname><given-names>Iqra</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Shah</surname><given-names>Muhammad Ajmal</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Hussain</surname><given-names>Ghulam</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Shafiq</surname><given-names>Nusrat</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Masood</surname><given-names>Muqaddas</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Adem</surname><given-names>&#x0015e;evki</given-names></name><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Sarker</surname><given-names>Satyajit D.</given-names></name><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Li</surname><given-names>Xiaomeng</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><aff id="aff1"><label>a</label>Department of Zoology, Faculty of Life Sciences, Government College University, Faisalabad, 38000, Pakistan</aff><aff id="aff2"><label>b</label>Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, 38000, Pakistan</aff><aff id="aff3"><label>c</label>Neurochemicalbiology and Genetics Laboratory (NGL), Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, 38000, Pakistan</aff><aff id="aff4"><label>d</label>Department of Chemistry, Government College Woman University, Faisalabad, 38000, Pakistan</aff><aff id="aff5"><label>e</label>The Key Laboratory of Molecular Epigenetics of MOE, Institute of Genetics and Cytology, Northeast Normal University, Changchun, 130024, China</aff><aff id="aff6"><label>f</label>Department of Chemistry, Faculty of Sciences, &#x000c7;ank&#x00131;r&#x00131; Karatekin University, Uluyaz&#x00131; Campus &#x000c7;ank&#x00131;r&#x00131;, Turkey</aff><aff id="aff7"><label>g</label>School of Pharmacy &#x00026; Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, England, UK</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author.</corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Corresponding author.</corresp></author-notes><pub-date pub-type="pmc-release"><day>6</day><month>8</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>11</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>6</day><month>8</month><year>2020</year></pub-date><volume>190</volume><fpage>110017</fpage><lpage>110017</lpage><history><date date-type="received"><day>5</day><month>5</month><year>2020</year></date><date date-type="rev-recd"><day>24</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>Nature as an infinite treasure of chemotypes and pharmacophores will continue to play an imperative role in the drug discovery. Natural products (NPs) such as plant and fungal metabolites have emerged as leads in drug discovery during recent years due to their efficacy, safety and selectivity. The current review summarizes natural sources as well as pharmacological potential of hispolon which is a major constituent of traditional medicinal mushroom <italic>Phellinus linteus</italic>. The study aims to update the scientific community about recent developments of hispolon in the arena of natural drugs by providing insights into its present status in therapeutic pursuits. Hispolon, a polyphenol has been reported to possess anticancer, antidiabetic, antioxidant, antiviral and anti-inflammatory activities. It fights against cancer <italic>via</italic> induction of apoptosis, halting cell cycle and inhibition of metastasis by targeting various cellular signaling pathways including PI3K/Akt, MAPK and NF-&#x003ba;B. The current review proposes that hispolon provides a novel opportunity for pharmacological applications and its styrylpyrone carbon skeleton might serve as an attractive scaffold for drug development. However, future researches are recommended to assess bioavailability, toxicological limits, pharmacokinetic and pharmacodynamic profiles of hispolon, in order to establish its potential as a potent multi-targeted drug in the near future.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" position="anchor"><alt-text id="alttext0010">Image 1</alt-text><graphic xlink:href="fx1_lrg"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd><italic>Phellinus linteus</italic></kwd><kwd>Hispolon</kwd><kwd>Anticancer</kwd><kwd>Antioxidant</kwd><kwd>Anti-inflammatory</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Natural products (NPs) have recently regained prominence in the arena of drug discovery due to increasing recognition of their pharmacological significance, biological functions and structural diversity (<xref rid="bib72" ref-type="bibr">Schmidt et al., 2007</xref>). The term &#x0201c;natural product&#x0201d; encompasses all the chemical compounds isolated from natural sources as fungi, plants and microorganisms (<xref rid="bib66" ref-type="bibr">Rasul et al., 2013</xref>). Humans have been extensively relying on nature for the fulfillment of their basic needs including food, shelter and cure of a wide spectrum of diseases (<xref rid="bib21" ref-type="bibr">Cragg and Newman, 2001</xref>). Over the three billion years, mother nature has refined her chemistry and after a long history of extensive research on nature, we are still only scratching the surface for analyzing nature's molecular diversity (<xref rid="bib22" ref-type="bibr">Cragg and Newman, 2013</xref>). Structural diversity is not the only reason but high selectivity, efficacy, specific biological activities, safety and cost effectiveness are additional features behind emerging significance of NPs in drug development (<xref rid="bib47" ref-type="bibr">Kennedy et al., 2009</xref>; <xref rid="bib82" ref-type="bibr">Veeresham, 2012</xref>).</p><p id="p0015">Although synthetic medicines gained popularity due to tringent regulation, time effectiveness and easy quality control, however, their potency and safety are always unreliable which led to the ultimate dependence of populations on NPs (<xref rid="bib82" ref-type="bibr">Veeresham, 2012</xref>). An analysis of drugs approved by FDA from 1981 to 2010 revealed that only 36% medicines were derived from synthetic molecules while more than half are either natural or derivative of NPs (<xref rid="bib5" ref-type="bibr">Atanasov et al., 2015</xref>). The most exciting nature-derived medicines including paclitaxel (anticancer drug) derived from the leaves of <italic>Taxus</italic> species and artemisinin (antimalarial drug) from <italic>Artemisia annua</italic> (L.) (<xref rid="bib99" ref-type="bibr">Sarfraz et al.2017</xref>). Folk medicine of European countries also uses fungus-derived medicinal substances to cure hepatitis, asthma and tumors. The fact that fungi could be a copious source of therapeutic molecules is affirmed from the discovery of penicillin (<xref rid="bib79" ref-type="bibr">Sulkowska-Ziaja et al., 2005</xref>). Advanced screening approaches based on innovative biological and chemical strategies have led to the identification of potent fungal metabolites in the recent years (<xref rid="bib73" ref-type="bibr">Schueffler and Anke, 2014</xref>).</p><p id="p0020">Polyphenols are diverse group of naturally occurring compounds with high industrial and medicinal potential (<xref rid="bib25" ref-type="bibr">Dos Santos et al., 2018</xref>). Mushrooms belonging to the genus <italic>Phellinus</italic> and <italic>Inonotus</italic> are identified as a good source of various polyphenolic compounds with a diverse pharmacological potential. Highly diverse and amply decorated mushroom-derived polyphenolic styrylpyrone scaffolds hold great promise for utilization in drug discovery (<xref rid="bib53" ref-type="bibr">Lee and Yun, 2011</xref>). One such bioactive styrylpyrone polyphenolic entity present in several mushrooms is hispolon (<xref rid="bib18" ref-type="bibr">Chethna et al., 2018a</xref>). Hispolon, a bioactive constituent of traditionally used medicinal mushrooms, exhibits a broad range of medicinal properties.</p><p id="p0025">The current review aims to update the scientific research community about natural sources and pharmacological potential of hispolon. The literature was searched <italic>via</italic> several e-sites such as PubMed, Science Direct, Scopus and Elsevier. Keywords used for searching of data were &#x0201c;hispolon and anticancer&#x0201d;, &#x0201c;hispolon and anti-inflammatory&#x0201d;, &#x0201c;hispolon and antidiabetic&#x0201d;, and &#x0201c;natural sources of hispolon&#x0201d;.</p><sec id="sec1.1"><label>1.1</label><title>Structure-activity relationship of hispolon and its derivatives</title><p id="p0030">Basically hispolon is a natural bioactive compound similar to cinnamic acid derivative (by replacement of <bold>H</bold> with-<bold>OH</bold> groups at <italic>meta</italic> and <italic>para</italic>-position in aromatic ring and &#x02013;<bold>OH</bold> by alkyl groups at the end of chain) as shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>
(<xref rid="bib10" ref-type="bibr">Bisogno et al., 2007</xref>).<fig id="fig1"><label>Fig. 1</label><caption><p>Hispolon from cinnamic acid.</p></caption><alt-text id="alttext0015">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0035">Structure-activity relationship (SAR) showed that the major factor responsible for greater activity of hispolon as compared to cinnamic acid is the &#x02013;<bold>COCH</bold>
<sub><bold>3</bold></sub> (<xref rid="bib10" ref-type="bibr">Bisogno et al., 2007</xref>). Substitution of different groups in basic skeleton of hispolon especially in aromatic phenyl ring played an excellent role in enhancing the biological activity. For example placement of methoxy group (<bold>-OCH</bold>
<sub><bold>3</bold></sub>) in phenyl ring increase the cytotoxicity but in comparison, the presence of hydroxyl (<bold>-OH</bold>) group decrease the cytotoxicity and this has been supposed to be due to greater lipocity of methoxy (-<bold>OCH</bold>
<sub><bold>3</bold></sub>) as compared to hydroxyl (<bold>OH</bold>) (<xref rid="bib10" ref-type="bibr">Bisogno et al., 2007</xref>; <xref rid="bib27" ref-type="bibr">Gaoa et al., 2018</xref>; <xref rid="bib68" ref-type="bibr">Rossia et al., 2019</xref>). Moreover, it has been observed that the position of substitution on hispolon skeleton also played a crucial role in enhancing its activity as shown in <xref rid="fig2" ref-type="fig">Fig. 2</xref>
. It has been observed that gingerdione and its analogues showed a clear difference in their activity affected by substituents in phenyl ring and its terminal part. For example, gingerdione has 10% sweetness as compared to its dehydro-derivative (<xref rid="bib66" ref-type="bibr">Rasul et al., 2013</xref>),-dehydrogingerdione that has 15% sweetness. Similar behavior has also observed in other gingerdione derivatives (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). It means that unsaturation or olefininc double bond and aromatic ring are very important in enhancing the activity (<xref rid="bib27" ref-type="bibr">Gaoa et al., 2018</xref>; <xref rid="bib54" ref-type="bibr">Ley et al., 2019</xref>).<fig id="fig2"><label>Fig. 2</label><caption><p>Structure-Activity relationship (SAR) of hispolon and its analogues.</p></caption><alt-text id="alttext0020">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p><p id="p0040">DFT (density-functional theory) and docking studies displayed that the different types of alkyl groups in alcoholic moiety of hispolon and its analogues has a great influence on the increment of activity as an electron-donating moieties including &#x02013;<bold>OME</bold>, -<bold>OH</bold>, -<bold>OAc</bold> increased the activity as compared to electron-withdrawing group as shown in <xref rid="fig2" ref-type="fig">Fig. 2</xref>, <xref rid="fig3" ref-type="fig">Fig. 3</xref>
(<xref rid="bib68" ref-type="bibr">Rossia et al., 2019</xref>; <xref rid="bib87" ref-type="bibr">Weia et al., 2020</xref>). These groups have different influences on activity as calculated by DFT. Introduction of the ester group raise the activity initially but at a specific length of alkyl chain in ester group has decrease effect. With the increase of alkyl chain in place of &#x02013;<bold>OMe, -OH</bold> or &#x02013;<bold>OAc</bold> reduce the activity by enhancing non-polar and less polar effect as compared to methoxy, hydroxyl and acetate group (<xref rid="fig2" ref-type="fig">Fig. 2</xref>, <xref rid="fig3" ref-type="fig">Fig. 3</xref>) (<xref rid="bib1" ref-type="bibr">Zhou et al., 2017</xref>). Additionally, SAR studies displayed that the tertiary alkyl groups showed greater activity as compared to linear alkyl groups due to the stearic hindrance that leads to improve the activity. Similarly, phenyl substitution enhances the activity while cyclohexyl decreases the activity. Similarly, by comparison of benzyl group and simple alkyl group, it has been observed that the benzyl group increases the activity more than a simple alkyl group (<xref rid="bib19" ref-type="bibr">Chethna et al., 2018b</xref>; <xref rid="bib87" ref-type="bibr">Weia et al., 2020</xref>).<fig id="fig3"><label>Fig. 3</label><caption><p>Effect of substitution on activity of hispolon and derivatives.</p></caption><alt-text id="alttext0025">Fig. 3</alt-text><graphic xlink:href="gr3_lrg"/></fig></p></sec></sec><sec id="sec2"><label>2</label><title>Natural sources of hispolon</title><p id="p0045">The nature-derived pharmacologically active polyphenol, hispolon is a yellow colored compound. It was firstly isolated in 1996 from <italic>Inonotus hispidus</italic> (<xref rid="bib2" ref-type="bibr">Ali et al., 1996</xref>). Hispolon has also been isolated from various species of Phellinus genus (<xref rid="fig4" ref-type="fig">Fig. 4</xref>
) such as <italic>Phellinus linteus</italic> (<xref rid="bib58" ref-type="bibr">Lu et al., 2009</xref>; <xref rid="bib63" ref-type="bibr">Paul et al., 2019</xref>), <italic>Phellinus igniarius</italic> (<xref rid="bib61" ref-type="bibr">Mo et al., 2004</xref>), <italic>Phellinus lonicerinus</italic> (<xref rid="bib84" ref-type="bibr">Wang et al., 2014</xref>) and <italic>Phellinus merrillii</italic> (<xref rid="bib12" ref-type="bibr">Chang et al., 2007</xref>). <xref rid="tbl1" ref-type="table">Table 1</xref>
presents yield of hispolon from natural sources and their pharmacological properties.<fig id="fig4"><label>Fig. 4</label><caption><p>Illustration of natural sources of hispolon.</p></caption><alt-text id="alttext0030">Fig. 4</alt-text><graphic xlink:href="gr4_lrg"/></fig><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Natural sources of hispolon, their biological activities.</p></caption><alt-text id="alttext0050">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Source</th><th>Common name</th><th>Parts used</th><th>Biological activities</th><th>Yield</th><th>References</th></tr></thead><tbody><tr><td align="left"><italic>Phellinus linteus</italic></td><td align="left">Black hoof mushroom</td><td align="left">Fruiting body, mycelium</td><td align="left">Anticancer, anti-inflammatory, immunomodulatory, antioxidant, antifungal antidiabetic, hepatoprotective, neuroprotective</td><td align="left">0.1629&#x000a0;mg/g of dried mushroom powder (95% ethanol, 6&#x000a0;h extraction time)</td><td align="left">(<xref rid="bib75" ref-type="bibr">Sliva, 2010</xref>; <xref rid="bib81" ref-type="bibr">Toopmuanga et al., 2014</xref>; <xref rid="bib17" ref-type="bibr">Chen et al., 2019</xref>)</td></tr><tr><td align="left"><italic>Phellinus igniarius</italic></td><td align="left">Willow bracket mushroom</td><td align="left">Fruiting body</td><td align="left">Antitumor, anti-oxidative, anti-inflammatory</td><td align="left">&#x02013;</td><td align="left">(<xref rid="bib51" ref-type="bibr">Kim et al., 2015</xref>; <xref rid="bib78" ref-type="bibr">Suabjakyong et al., 2015</xref>)</td></tr><tr><td align="left"><italic>Inonotus hispidus</italic></td><td align="left">Shaggy bracket mushroom</td><td align="left">Fruiting body</td><td align="left">Antimicrobial, antiviral, antioxidant, anti-inflammatory, immunomodulatory, antiproliferative</td><td align="left">0.06% (60 mg/1&#x000a0;g EtOAc extract)</td><td align="left">(<xref rid="bib3" ref-type="bibr">An and Jia, 1987</xref>; <xref rid="bib2" ref-type="bibr">Ali et al., 1996</xref>)</td></tr><tr><td align="left"><italic>Phellinus merrillii</italic></td><td align="left">Sangwhang</td><td align="left">Fruiting body</td><td align="left">Hepatoprotective and antioxidant</td><td align="left">&#x02013;</td><td align="left">(<xref rid="bib12" ref-type="bibr">Chang et al., 2007</xref>; <xref rid="bib41" ref-type="bibr">Huang et al., 2011a</xref>)</td></tr><tr><td align="left"><italic>Phellinus lonicerinus</italic></td><td align="left">&#x02013;</td><td align="left">Fruiting body</td><td align="left">Anti-tumor, anti-proliferation</td><td align="left">&#x02013;</td><td align="left"><xref rid="bib84" ref-type="bibr">Wang et al. (2014)</xref></td></tr></tbody></table></table-wrap></p></sec><sec id="sec3"><label>3</label><title>Biological activities of hispolon</title><p id="p0050">The bioactive natural compound, hispolon, has been reported to possess pharmacological activities such as anti-oxidant (<xref rid="bib16" ref-type="bibr">Chen et al., 2014</xref>), anti-tumor (<xref rid="bib39" ref-type="bibr">Hsin et al., 2017</xref>), antiviral (<xref rid="bib6" ref-type="bibr">Awadh Ali et al., 2003</xref>), anti-inflammatory (<xref rid="bib67" ref-type="bibr">Ravindran et al., 2010</xref>), hepatoprotective (<xref rid="bib12" ref-type="bibr">Chang et al., 2007</xref>), immunomodulatory (<xref rid="bib30" ref-type="bibr">Grundemann et al., 2016</xref>) and anti-diabetic (<xref rid="bib15" ref-type="bibr">Chen et al., 2013</xref>). <xref rid="fig5" ref-type="fig">Fig. 5</xref>
presents the various pharmacological activities of hispolon.<fig id="fig5"><label>Fig. 5</label><caption><p>Illustration of major biological activities of hispolon.</p></caption><alt-text id="alttext0035">Fig. 5</alt-text><graphic xlink:href="gr5_lrg"/></fig></p><sec id="sec3.1"><label>3.1</label><title>Anticancer activity</title><p id="p0055">Cancer is a multi&#x02010;factorial disease caused by genetic alterations as well as environmental factors which coordinately trigger neoplastic transformations <italic>via</italic> activation of oncogenes or inactivation of tumor suppressor genes (<xref rid="bib48" ref-type="bibr">Khan et al., 2016</xref>). Current treatment opportunities for this deadly disease include chemotherapy which often exhibits high toxicity and low tumor specificity (<xref rid="bib71" ref-type="bibr">Schirrmacher, 2019</xref>). Poor efficacy and non-selectivity of chemotherapeutics is a matter of great concern from several years (<xref rid="bib43" ref-type="bibr">Huang et al., 2017</xref>). In this context, naturally occurring bioactive compounds are becoming a novel source for drug discovery against cancer due to their selectivity, safety and cost effectiveness (<xref rid="bib43" ref-type="bibr">Huang et al., 2017</xref>).</p><p id="p0060">From 136 approved drugs against cancer during 1981&#x02013;2014, only 17% were of synthetic origin while 83% of these drugs were derived from natural compounds or based on natural scaffolds (<xref rid="bib24" ref-type="bibr">Demain and Vaishnav, 2011</xref>). Several natural compounds such as taxols, brassinosteroids and polyphenols possess high efficacy to fight various cancers (<xref rid="bib28" ref-type="bibr">Greenwell and Rahman, 2015</xref>). Polyphenols are significantly abundant in dietary foods and their contribution in the prevention of cardiovascular diseases and cancer is emerging now a days (<xref rid="bib59" ref-type="bibr">Manach et al., 2004</xref>).</p><p id="p0065">Hispolon has been affirmed to possess antiproliferative activity against U87MG (glioblastoma) (<xref rid="bib4" ref-type="bibr">Arcella et al., 2017</xref>), HeLa, SiHa (cervical cancer) (<xref rid="bib39" ref-type="bibr">Hsin et al., 2017</xref>), MCF-7, MDA-MB-231 (breast carcinoma) (<xref rid="bib86" ref-type="bibr">Wang et al., 2017</xref>), NPC-39, HONE-1, NPC-BM, NPC-039 (nasopharyngeal cancer) (<xref rid="bib33" ref-type="bibr">Ho et al., 2017</xref>), A549, H661 (lung cancer) (<xref rid="bib89" ref-type="bibr">Wu et al., 2014</xref>), DU145, LNCaP, PC3 (prostate cancer) (49318940), MV4-11, HL-60, U937, THP-1 (leukemia) (<xref rid="bib36" ref-type="bibr">Hsiao et al., 2013</xref>), SGC-7901, MKN-45, MGC-803 (gastric cancer) (<xref rid="bib14" ref-type="bibr">Chen et al., 2008</xref>), T24, J82 (bladder cancer) (<xref rid="bib58" ref-type="bibr">Lu et al., 2009</xref>), Hep3B, SK-Hep1 (hepatocellular carcinoma) (<xref rid="bib42" ref-type="bibr">Huang et al., 2011b</xref>), TCMK-1 (renal cancer) (<xref rid="bib96" ref-type="bibr">Yun et al., 2019</xref>) and KB (human epidermoid) (<xref rid="bib13" ref-type="bibr">Chen et al., 2006</xref>) cancer cells. The anticancer efficacy of hispolon against several cancers types is shown in <xref rid="fig6" ref-type="fig">Fig. 6</xref>
.<fig id="fig6"><label>Fig. 6</label><caption><p>Anticancer potential of hispolon against various types of cancer.</p></caption><alt-text id="alttext0040">Fig. 6</alt-text><graphic xlink:href="gr6_lrg"/></fig></p><sec id="sec3.1.1"><label>3.1.1</label><title>Hispolon and cell cycle arrest</title><p id="p0070">Cell cycle is an extremely controlled process involving complex cascade of events and dysregulation of this control leads to the development of cancer (<xref rid="bib8" ref-type="bibr">Bailon-Moscoso et al., 2017</xref>). Cell cycle progression is under control of regulatory proteins such as cyclins, CDKs (cyclin-dependent kinases) and tumor suppressor genes such as p53 (<xref rid="bib70" ref-type="bibr">Sanchez and Dynlacht, 2005</xref>; <xref rid="bib85" ref-type="bibr">Wang et al., 2015</xref>). Nature-derived bioactive compounds have promising ability to modulate the expression of various cyclins, CDKs and CDK inhibitors (CKIs), thus, halting proliferation in human cancers (<xref rid="bib46" ref-type="bibr">Johansson and Persson, 2008</xref>).</p><p id="p0075">Hispolon has potential to halt cell cycle in several cancer cells at G0/G1 and G2/M phase. In the human NB4 (promyelocytic leukemia) cells, hispolon caused cell cycle arrest at G0/G1with a marked reduction in CDK4, CDK2, cyclin E and cyclin D1 levels (<xref rid="bib15" ref-type="bibr">Chen et al., 2013</xref>). Hispolon induced G2/M arrest and inhibited the cell viability of glioblastoma U87MG cells by increasing the level of CDK inhibitor, p21 (<xref rid="bib4" ref-type="bibr">Arcella et al., 2017</xref>). Down-regulation of cyclins A and E contributed towards hispolon-stimulated S phase arrest with up-regulation of p27Kip1 and p21waf1/Cip1 expression in Hep3B cells (<xref rid="bib42" ref-type="bibr">Huang et al., 2011b</xref>). Hispolon has also been reported to induce S phase arrest in DU145&#x000a0;cells by downregulating cyclin B1, cyclin D1 and CDK4 (<xref rid="bib60" ref-type="bibr">Masood et al., 2019</xref>). The distribution of hispolon treated lung cancer cells (A549 and H661) in different phase of cell cycle showed that hispolon treatment increased the accumulations of these cells in G0/G1 phase (<xref rid="bib89" ref-type="bibr">Wu et al., 2014</xref>). However, there is lack of evidences about phase specific cell cycle inhibitory potential of hispolon in various cancers such as whether hispolon halted cell cycle at G2, M, G0 or G1 phase which needs to be investigated in future studies.</p></sec><sec id="sec3.1.2"><label>3.1.2</label><title>Hispolon and apoptosis</title><p id="p0080">Apoptosis is a highly systemized mode of cell death that is characterized by energy-dependent biochemical events and distinct morphological characteristics (<xref rid="bib26" ref-type="bibr">Elmore, 2007</xref>). Defective apoptotic pathways have critical role in the onset and pathogenesis of cancer, thus, induction of apoptosis is a feasible and targeted treatment in various types of cancer (<xref rid="bib88" ref-type="bibr">Wong, 2011</xref>). The two majorly described apoptotic pathways are extrinsic/death receptor pathways and intrinsic/mitochondrial-mediated pathway (<xref rid="bib7" ref-type="bibr">Baig et al., 2016</xref>). Extrinsic cellular pathway is characterized by the activation of death signaling ligands such as Fas-L (Fas ligand) (<xref rid="bib44" ref-type="bibr">Jan and Chaudhry, 2019</xref>). The intrinsic pathway is mediated by Bcl-2 (B-cell lymphoma 2) family members such as activation of mitochondrial membrane bounded Bax (Bcl2-associated X protein) and inactivation of Bcl-2 stimulate the discharge of cytochrome c which in turn activates initiator and effector caspases to induce the apoptosis (<xref rid="bib57" ref-type="bibr">Loreto et al., 2014</xref>).</p><p id="p0085">Natural bioactive compounds induce the activation of apoptotic pathways in cancer cells (<xref rid="bib69" ref-type="bibr">Safarzadeh et al., 2014</xref>). Hispolon, an active polyphenolic compound sensitizes cancer cells to trail by activating caspase-3, -8 and -9, reducing Bcl-2, Bcl-xL while upregulating Bax protein (<xref rid="bib52" ref-type="bibr">Kim et al., 2016</xref>). In DU145&#x000a0;cells, hispolon modulates Bcl-2 family proteins leading towards the discharge of cytochrome c that ultimately triggers the cascade of caspases (<xref rid="fig7" ref-type="fig">Fig. 7</xref>
) (<xref rid="bib60" ref-type="bibr">Masood et al., 2019</xref>). Anticancer efficacy of hispolon is linked with the upregulation of Fas and Fas ligand that stimulates extrinsic apoptotic pathway (<xref rid="bib15" ref-type="bibr">Chen et al., 2013</xref>; <xref rid="bib38" ref-type="bibr">Hsieh et al., 2018</xref>). Molecular targets of hispolon, model cell lines used in experimentation, IC<sub>50</sub> and treatment conditions are presented in <xref rid="tbl2" ref-type="table">Table 2</xref>
.<fig id="fig7"><label>Fig. 7</label><caption><p>Diagrammatic representation of hispolon's anticancer mechanism of action. Hispolon targets various nuclear, cytoplasmic and membranous proteins to induce apoptosis, halt metastasis and cell cycle in several cancer types.</p></caption><alt-text id="alttext0045">Fig. 7</alt-text><graphic xlink:href="gr7_lrg"/></fig><table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Molecular targets of hispolon in various cancer types.</p></caption><alt-text id="alttext0055">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Cancer type</th><th>Cell line</th><th>No. of cells/well</th><th>Treatment time</th><th>IC<sub>50</sub></th><th>Molecular targets</th><th>Cell cycle arrest</th><th>References</th></tr></thead><tbody><tr><td align="left">Glioblastoma</td><td align="left">U87MG</td><td align="left">1&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup></td><td align="left">24, 48, 72&#x000a0;h</td><td align="left">&#x02013;</td><td align="left">Cyclin D4&#x02193;, p2&#x02191;, p53&#x02191;, CDK4&#x02193;, p-ERK 1&#x02193;1</td><td align="left">G2/M</td><td align="left"><xref rid="bib4" ref-type="bibr">Arcella et al. (2017)</xref></td></tr><tr><td align="left">Cervical</td><td align="left">HeLa, SiHa</td><td align="left">7&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup></td><td align="left">24&#x000a0;h</td><td align="left">&#x02013;</td><td align="left">p-AKT&#x02193;, ERK <sup>Act</sup>, LC3- II&#x02191;, MMP-2&#x02193;, MMP-9&#x02193;</td><td align="left">&#x02013;</td><td align="left"><xref rid="bib39" ref-type="bibr">Hsin et al. (2017)</xref></td></tr><tr><td align="left">Breast</td><td align="left">MCF-7, T47D, MDA-MB-231</td><td align="left">5&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup>, 5&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup></td><td align="left">24&#x000a0;h</td><td align="left">70&#x000a0;Mm</td><td align="left">ER&#x003b1;&#x02193;, PARP&#x02191;, Bcl-2&#x02193;, E-cadherin&#x02193;, MMP-9&#x02193;, p-I&#x003ba;B&#x003b1;&#x02534;, p- NF-&#x003ba;B&#x02193;</td><td align="left">&#x02013;</td><td align="left">(<xref rid="bib45" ref-type="bibr">Jang et al., 2015</xref>; <xref rid="bib80" ref-type="bibr">Sun et al., 2015</xref>; <xref rid="bib98" ref-type="bibr">Zhao et al., 2016</xref>; <xref rid="bib86" ref-type="bibr">Wang et al., 2017</xref>)</td></tr><tr><td align="left">Naso-pharyngeal</td><td align="left">HONE-1, NPC-39, NPC-BM, NPC-039</td><td align="left">5&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">p-Akt&#x02534;, uPA&#x02534;, MMP-2&#x02193;, MMP-9&#x02193;, caspase-3 <sup>Act</sup>, caspase-8 <sup>Act</sup>, caspase-9 <sup>Act</sup></td><td align="left">&#x02013;</td><td align="left">(<xref rid="bib37" ref-type="bibr">Hsieh et al., 2014</xref>; <xref rid="bib33" ref-type="bibr">Ho et al., 2017</xref>)</td></tr><tr><td align="left">Lung</td><td align="left">A549, H661</td><td align="left">1&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup></td><td align="left">24, 48, 72&#x000a0;h</td><td align="left">35.9&#x000a0;&#x000b1;&#x000a0;6.9, 28.8&#x000a0;&#x000b1;&#x000a0;3.1, 8.1&#x000a0;&#x000b1;&#x000a0;2.3&#x000a0;&#x003bc;M</td><td align="left">Cyclin D1&#x02193;, CDK2&#x02193;, CDK4&#x02193;, cyclin E&#x02193;, CDK6&#x02193;, p27&#x02191;, p21&#x02191;</td><td align="left">G0/G1</td><td align="left"><xref rid="bib89" ref-type="bibr">Wu et al. (2014)</xref></td></tr><tr><td align="left">Prostate</td><td align="left">DU145, LNCaP, PC3</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">31&#x000a0;&#x003bc;M, 30&#x000a0;&#x003bc;M, 28&#x000a0;&#x003bc;M</td><td align="left">cyclin B1&#x02193;, cyclin D1&#x02193;, CDK4&#x02193;, p21&#x02191;, p-STAT3&#x02193;</td><td align="left">S phase</td><td align="left"><xref rid="bib60" ref-type="bibr">Masood et al. (2019)</xref></td></tr><tr><td align="left">Leukemia</td><td align="left">NB4, OCI-AML3</td><td align="left">1&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup></td><td align="left">12, 24, 48&#x000a0;h</td><td align="left">7.98, 2.26&#x000a0;&#x003bc;g/mL</td><td align="left">Fas&#x02191;, FasL&#x02191;, Bcl-2&#x02193;, PARP&#x02191;, caspase-9&#x02191;, Bax&#x02191;, caspase-3&#x02191; p53&#x02191;, p27&#x02191;, p21&#x02191;, CDK2&#x02193;, CDK4&#x02193;, cyclin E&#x02193;, cyclin D1&#x02193;</td><td align="left">G0/G1</td><td align="left"><xref rid="bib15" ref-type="bibr">Chen et al. (2013)</xref></td></tr><tr><td align="left">Acute myeloid Leukemia</td><td align="left">MOLM-13, HL-60, MV4-11, U937, THP-1</td><td align="left">1&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup></td><td align="left">24&#x000a0;h</td><td align="left">25 &#x0039c;m</td><td align="left">Caspase-3 <sup>Act</sup>, caspase-8 <sup>Act</sup>, caspase-9 <sup>Act</sup>, PARP&#x02191;</td><td align="left">&#x02013;</td><td align="left"><xref rid="bib36" ref-type="bibr">Hsiao et al. (2013)</xref></td></tr><tr><td align="left">Gastric</td><td align="left">SGC-7901, MGC-803, MKN-45</td><td/><td align="left">24, 48,72&#x000a0;h</td><td align="left">15.6, 11.4, 7.5&#x000a0;&#x003bc;g/mL</td><td align="left">Caspase-3 <sup>Act</sup>, caspase-9 <sup>Act</sup>, Bax&#x02191;, Bak&#x02191;, Bcl-2&#x02193;, Bcl-xL&#x02193;, ROS&#x02191;</td><td align="left">&#x02013;</td><td align="left"><xref rid="bib14" ref-type="bibr">Chen et al. (2008)</xref></td></tr><tr><td align="left">Bladder</td><td align="left">T24, J82</td><td align="left">2&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup></td><td align="left">&#x02013;</td><td align="left">10&#x000a0;&#x003bc;g/mL,<break/>40&#x000a0;&#x003bc;g/mL</td><td align="left">p-21&#x02191;</td><td align="left">G2/M</td><td align="left"><xref rid="bib58" ref-type="bibr">Lu et al. (2009)</xref></td></tr><tr><td align="left">Hepatocellular</td><td align="left">Hep3B, SK-Hep1</td><td align="left">2&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup></td><td align="left">24&#x000a0;h</td><td align="left">&#x02013;</td><td align="left">cyclin A&#x02193;, cyclin E&#x02193;, CDK2&#x02193;, JNK <sup>Act</sup>, p38 MAPK <sup>Act</sup> MMP-2&#x02193;, MMP-9&#x02193;, uPA&#x02193;, FAK&#x02193;</td><td align="left">S phase</td><td align="left">(<xref rid="bib40" ref-type="bibr">Huang et al., 2010</xref>, <xref rid="bib42" ref-type="bibr">2011b</xref><xref rid="bib40" ref-type="bibr">bib_Huang_et_al_2010</xref><xref rid="bib42" ref-type="bibr">bib_Huang_et_al_2011b</xref>)</td></tr><tr><td align="left">Epithelial</td><td/><td align="left">1&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup></td><td align="left">24&#x000a0;h</td><td align="left">&#x02013;</td><td align="left">Snail&#x02193;, Twist&#x02193;</td><td align="left">&#x02013;</td><td align="left"><xref rid="bib35" ref-type="bibr">Hong et al. (2017)</xref></td></tr><tr><td align="left">Renal</td><td align="left">TCMK-1</td><td/><td/><td/><td align="left">TRAIL&#x02191;</td><td align="left">&#x02013;</td><td align="left"><xref rid="bib96" ref-type="bibr">Yun et al. (2019)</xref></td></tr><tr><td align="left">Human Epidermoid</td><td align="left">KB cells</td><td align="left">5&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup></td><td align="left">&#x02013;</td><td align="left">4.62&#x000a0;&#x000b1;&#x000a0;0.16&#x000a0;&#x003bc;g/mL</td><td align="left">Caspase-3 <sup>Act</sup></td><td align="left">&#x02013;</td><td align="left"><xref rid="bib13" ref-type="bibr">Chen et al. (2006)</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Cyclin dependent kinase 4 (CDK4); Protein kinase B (Akt); light chain 3 (LC3); matrix metalloproteinase (MMP); poly-ADP ribose polymerase (PARP); Fas ligand (FasL); Mitogen activated protein kinase (MAPK); Reactive oxygen species (ROS); Zinc finger protein SNAI1 (Snail); TNF-related apoptosis-inducing ligand (TRAIL);&#x000a0;Focal adhesion kinase (FAK).</p></fn></table-wrap-foot></table-wrap></p><sec id="sec3.1.2.1"><label>3.1.2.1</label><title>Hispolon and NF-&#x003ba;B (nuclear factor-&#x003ba;B) signaling pathway</title><p id="p0090">NF-&#x003ba;B, family of transcriptional factors serve as master regulators of immune and inflammatory processes (<xref rid="bib62" ref-type="bibr">Napetschnig and Wu, 2013</xref>). This five membered family is identified as a crucial player in many games of cancer progression (<xref rid="bib34" ref-type="bibr">Hoesel and Schmid, 2013</xref>). An inhibitor protein known as I&#x003ba;B interacts with NF-&#x003ba;B in cytoplasm to control the translocation and subsequent activity of NF-&#x003ba;B. Activation of NF-&#x003ba;B and its translocation towards nucleus is controlled by I&#x003ba;B phosphorylation and degradation. Once in the nucleus, NF-&#x003ba;B binds to target DNA and induce transcriptional activation of various genes involved in cell growth and inflammation, thus, playing an imperative role in cancer and inflammatory disorders (<xref rid="bib9" ref-type="bibr">Baldwin, 1996</xref>). In tumor cells, NF-&#x003ba;B is found to be constitutively activated and its suppression leads to tumor regression (<xref rid="bib91" ref-type="bibr">Xia et al., 2014</xref>).</p><p id="p0095">Hispolon reduced the phosphorylation of I&#x003ba;B&#x003b1; which suppressed the translocation of NF-&#x003ba;B towards nucleus. Inhibition of NF-&#x003ba;B translocation down-regulated the expression of its down-stream encoded protein, MMP-9 (matrix metalloproteinase-9) which reduced the invasive capabilities of MDA-MB231&#x000a0;cells (<xref rid="bib80" ref-type="bibr">Sun et al., 2015</xref>). Although inhibition of I&#x003ba;B has been reported as a possible mechanism of hispolon induced NF-&#x003ba;B inhibition, however the alteration in phosphorylation of p65 or p50 subunits by hispolon to deactivate NF-&#x003ba;B translocation needs to be investigated.</p></sec><sec id="sec3.1.2.2"><label>3.1.2.2</label><title>Hispolon, MAPK and PI3K/Akt signaling pathways</title><p id="p0100">The MAPKs (mitogen activated protein kinases) mediate several cellular activities involved in the cancer progression such as evading apoptosis, inducing proliferation and immune escape (<xref rid="bib11" ref-type="bibr">Cargnello and Roux, 2011</xref>; <xref rid="bib64" ref-type="bibr">Peluso et al., 2019</xref>). MAPK family includes following members: c-Jun N terminal kinase (JNK), ERK (extracellular signal-regulated kinase) and the p38 MAPK (<xref rid="bib76" ref-type="bibr">Soares-Silva et al., 2016</xref>). Phosphatidylinositol 3-kinase (PI3K)/Akt is one of the most important intracellular pathway that perform several important roles in proliferation, cell growth and survival which makes it an attractive target for cancer therapy (<xref rid="bib94" ref-type="bibr">Yang et al., 2019</xref>).</p><p id="p0105">Polyphenols have been known for their potential of targeting protein kinases <italic>via</italic> interacting with the ATP-binding sites (<xref rid="bib32" ref-type="bibr">Guerra and Issinger, 2019</xref>). Hispolon inhibited NPC cell metastasis by downregulating Akt signaling pathway (<xref rid="bib33" ref-type="bibr">Ho et al., 2017</xref>). Hispolon treatment leads toward increased phosphorylation of p38 MAPK, JNK and ERK1/2 in HONE-1 and NPC-039&#x000a0;cells (<xref rid="bib38" ref-type="bibr">Hsieh et al., 2018</xref>).</p></sec></sec><sec id="sec3.1.3"><label>3.1.3</label><title>Anti-metastatic effects of hispolon</title><p id="p0110">Metastasis is a primary cause of mortalities and most complicated obstacle in the development of effective cancer therapies (<xref rid="bib98" ref-type="bibr">Zhao et al., 2016</xref>). Metastasis is characterized by four important steps: detachment, migration and adhesion of cancer cells to secondary sites. Cancer cell motility, extracellular matrix degradation, angiogenesis and epithelial mesenchymal transition (EMT) serve as initiating factors for metastatic transformations (<xref rid="bib31" ref-type="bibr">Guan, 2015</xref>). Thus, targeting metastatic niche, EMT and other metastasis initiating factors could lead towards successful cancer therapies (<xref rid="bib95" ref-type="bibr">Yoo et al., 2018</xref>).</p><p id="p0115">Hispolon treatment inhibited the invasive capabilities of HeLa and SiHa cells <italic>via</italic> blocking ERK pathway (<xref rid="bib39" ref-type="bibr">Hsin et al., 2017</xref>). Hispolon exerts anti-metastatic effects by the inhibition of uPA (Urokinase plasminogen activator) <italic>via</italic> the Akt pathway in nasopharyngeal cancer cells (<xref rid="bib33" ref-type="bibr">Ho et al., 2017</xref>). By reducing the expression of MMP-2, MMP-9 and uPA, hispolon inhibited the metastasis in SK-Hep1 cells (<xref rid="bib40" ref-type="bibr">Huang et al., 2010</xref>). Furthermore, hispolon suppresses invasive potential of cancer cells <italic>via</italic> EMT inhibition. Therefore, hispolon may be a novel anti-metastatic agent (<xref rid="bib35" ref-type="bibr">Hong et al., 2017</xref>). As EMT has close association with drug resistance, further studies should also investigate whether hispolon has potential to sensitize cancer cells towards chemo-drugs.</p></sec></sec><sec id="sec3.2"><label>3.2</label><title>Antioxidant activity</title><p id="p0120">Overproduced ROS (reactive oxygen species) and free radicals cause DNA damage, induce mutations, impair protiens and react with membranes that serve as predisposing factor for age-related diseases and cancer (<xref rid="bib49" ref-type="bibr">Khansari et al., 2009</xref>). Antioxidants derived from mushrooms, cereals, spices, vegetables and traditional medicinal herbs exhibit a broad range of biological activities such as anticancer, anti-aging and anti-inflammatory (<xref rid="bib97" ref-type="bibr">Zhang et al., 2015</xref>; <xref rid="bib92" ref-type="bibr">Xu et al., 2017</xref>). Therefore, antioxidants could save human body from the harmful effects of free radicals by scavenging and neutralizing powers. Hispolon isolated from <italic>Inonotus hispidius</italic> shows a strong antioxidant activity (<xref rid="bib83" ref-type="bibr">Venkateswarlu et al., 2010</xref>). Recently, hispolon and its derivatives have also been reported to exhibit ROS scavenging activities in cell-free systems (<xref rid="bib18" ref-type="bibr">Chethna et al., 2018a</xref>), affirming its potential as antioxidant agent.</p></sec><sec id="sec3.3"><label>3.3</label><title>Antiviral activity</title><p id="p0125">The emergence and re-emergence of viral epidemics arouses the urgent need to develop effective anti-viral therapeutics (<xref rid="bib23" ref-type="bibr">De Clercq, 2004</xref>). In addition, viruses also contribute to 15% of the total human cancers (<xref rid="bib55" ref-type="bibr">Liao, 2006</xref>). In this context, nature-derived agents have potential to prevent and treat viral infections (<xref rid="bib74" ref-type="bibr">Sencanski et al., 2015</xref>). It has been reported that hispolon exhibits significant anti-viral activity (<xref rid="bib14" ref-type="bibr">Chen et al., 2008</xref>; <xref rid="bib93" ref-type="bibr">Yang et al., 2014</xref>). Hispolon, isolated from ethanolic extracts of <italic>Inonotus hispidus</italic> fruiting bodies, showed potent anti-viral activity against influenza virus A and B (<xref rid="bib6" ref-type="bibr">Awadh Ali et al., 2003</xref>). Thus, the antiviral activity of this phenolic compound recommends that its efficacy against other viruses such as coronaviruses should also be investigated.</p></sec><sec id="sec3.4"><label>3.4</label><title>Anti-inflammatory activity</title><p id="p0130">Inflammation is a response of the body defense system against infections and tissue damage (<xref rid="bib65" ref-type="bibr">Punchard et al., 2004</xref>). Adverse effects associated with non-steroidal anti-inflammatory drugs (NSAIDs) arouse the need to develop safe alternatives for the treatment of chronic inflammations (<xref rid="bib77" ref-type="bibr">Sostres et al., 2010</xref>). Hispolon induces potent anti-inflammatory response by suppressing TNF-&#x003b1; (tumor necrosis factor-&#x003b1;) (<xref rid="bib56" ref-type="bibr">Lin et al., 2014</xref>), and decreasing MMP-9 <italic>via</italic> inhibition of NF-&#x003ba;B pathway (<xref rid="bib80" ref-type="bibr">Sun et al., 2015</xref>). Anti-inflammatory actions of hispolon occur <italic>via</italic> inhibition of JNK phosphorylation (<xref rid="bib93" ref-type="bibr">Yang et al., 2014</xref>). Hispolon possesses inhibitory activity against LPS-induced inflammation <italic>via</italic> inhibiting JNK and NF-kB while upregulating HO-1 (Heme oxygenase-1) protein in BV-2&#x000a0;cells (<xref rid="bib90" ref-type="bibr">Wu et al., 2017</xref>).</p></sec><sec id="sec3.5"><label>3.5</label><title>Antidiabetic activity</title><p id="p0135">Diabetes mellitus is characterized by hyperglycemia which is caused by defects in insulin secretion, its action or both (<xref rid="bib50" ref-type="bibr">Kharroubi and Darwish, 2015</xref>). Alpha-glucosidase and aldose reductase are emerging metabolic targets for the treatment of patients with impaired glucose tolerance and diabetes (<xref rid="bib29" ref-type="bibr">Grewal et al., 2016</xref>). Herbal medicines have a long history for the treatment of diabetes as compared to conventional medicine (<xref rid="bib20" ref-type="bibr">Choudhury et al., 2018</xref>). Hispolon, a natural polyphenolic compound possesses strong antidiabetic properties (<xref rid="bib15" ref-type="bibr">Chen et al., 2013</xref>). Hispolon exhibited potent activity against &#x003b1;-glucosidase (IC<sub>50</sub>&#x000a0;=&#x000a0;12.38&#x000a0;&#x003bc;g/mL) and aldose reductase (IC<sub>50</sub>&#x000a0;=&#x000a0;9.47&#x000a0;&#x003bc;g/mL). These findings suggest that hispolon might serve as an attractive scaffold for anti-diabetic drugs (<xref rid="bib41" ref-type="bibr">Huang et al., 2011a</xref>).</p></sec></sec><sec id="sec4"><label>4</label><title>Conclusions</title><p id="p0140">Conclusively, hispolon is a smaller molecule with greater potential and more cell specificity. Since its first isolation in 1996 till now its cytotoxic potential against thirteen different types of cancers has been reported. As more than 200 types of cancers are known, thus, its efficacy against other cancers should also be investigated. Critical analysis of IC<sub>50</sub> of hispolon against cancers revealed that it possess very good efficacy against breast cancer, suggesting that further studies should be conducted to validate its potential against breast cancer. Hispolon targets multiple pathways including PI3K/Akt, MAPK and NF-&#x003ba;B in cancer cells to induce apoptosis and reduce their metastatic capabilities. Regarding the disease complexity, cancer is more likely to be alleviated or healed though simultaneous modulation of multiple targets, in this context hispolon might emerge as an attractive scaffold for the development of a multitargeted anticancer drug. The reported data suggests that hispolon possess significant efficacy as well as safety for its pharmacological applications. Thus, it would be worthwhile to conduct further studies to determine the bioavailability, toxicological limits and ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) profile of hispolon to fill the room of knowledge for its validation as a potential anticancer agent.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0150">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>N.A.A.</given-names></name><name><surname>Jansen</surname><given-names>R.</given-names></name><name><surname>Pilgrim</surname><given-names>H.</given-names></name><name><surname>Liberra</surname><given-names>K.</given-names></name><name><surname>Lindequist</surname><given-names>U.</given-names></name></person-group><article-title>HISPOLON, a yellow pigment from inonotus hispidus</article-title><source>Phytochemistry</source><volume>41</volume><year>1996</year><fpage>927</fpage><lpage>929</lpage></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>An</surname><given-names>P.</given-names></name><name><surname>Jia</surname><given-names>K.M.</given-names></name></person-group><article-title>[Relation between anti-Dane particle antibody and polymerized human serum albumin receptor]</article-title><source>Zhonghua Nei Ke Za Zhi</source><volume>26</volume><year>1987</year><fpage>711</fpage><lpage>713</lpage><comment>743</comment><pub-id pub-id-type="pmid">2837367</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Arcella</surname><given-names>A.</given-names></name><name><surname>Oliva</surname><given-names>M.A.</given-names></name><name><surname>Sanchez</surname><given-names>M.</given-names></name><name><surname>Staffieri</surname><given-names>S.</given-names></name><name><surname>Esposito</surname><given-names>V.</given-names></name><name><surname>Giangaspero</surname><given-names>F.</given-names></name><name><surname>Cantore</surname><given-names>G.</given-names></name></person-group><article-title>Effects of hispolon on glioblastoma cell growth</article-title><source>Environ. Toxicol.</source><volume>32</volume><year>2017</year><fpage>2113</fpage><lpage>2123</lpage><pub-id pub-id-type="pmid">28618133</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Atanasov</surname><given-names>A.G.</given-names></name><name><surname>Waltenberger</surname><given-names>B.</given-names></name><name><surname>Pferschy-Wenzig</surname><given-names>E.M.</given-names></name><name><surname>Linder</surname><given-names>T.</given-names></name><name><surname>Wawrosch</surname><given-names>C.</given-names></name><name><surname>Uhrin</surname><given-names>P.</given-names></name><name><surname>Temml</surname><given-names>V.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Schwaiger</surname><given-names>S.</given-names></name><name><surname>Heiss</surname><given-names>E.H.</given-names></name><name><surname>Rollinger</surname><given-names>J.M.</given-names></name><name><surname>Schuster</surname><given-names>D.</given-names></name><name><surname>Breuss</surname><given-names>J.M.</given-names></name><name><surname>Bochkov</surname><given-names>V.</given-names></name><name><surname>Mihovilovic</surname><given-names>M.D.</given-names></name><name><surname>Kopp</surname><given-names>B.</given-names></name><name><surname>Bauer</surname><given-names>R.</given-names></name><name><surname>Dirsch</surname><given-names>V.M.</given-names></name><name><surname>Stuppner</surname><given-names>H.</given-names></name></person-group><article-title>Discovery and resupply of pharmacologically active plant-derived natural products: a review</article-title><source>Biotechnol. Adv.</source><volume>33</volume><year>2015</year><fpage>1582</fpage><lpage>1614</lpage><pub-id pub-id-type="pmid">26281720</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Awadh Ali</surname><given-names>N.A.</given-names></name><name><surname>Mothana</surname><given-names>R.A.</given-names></name><name><surname>Lesnau</surname><given-names>A.</given-names></name><name><surname>Pilgrim</surname><given-names>H.</given-names></name><name><surname>Lindequist</surname><given-names>U.</given-names></name></person-group><article-title>Antiviral activity of Inonotus hispidus</article-title><source>Fitoterapia</source><volume>74</volume><year>2003</year><fpage>483</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">12837367</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Baig</surname><given-names>S.</given-names></name><name><surname>Seevasant</surname><given-names>I.</given-names></name><name><surname>Mohamad</surname><given-names>J.</given-names></name><name><surname>Mukheem</surname><given-names>A.</given-names></name><name><surname>Huri</surname><given-names>H.Z.</given-names></name><name><surname>Kamarul</surname><given-names>T.</given-names></name></person-group><article-title>Potential of apoptotic pathway-targeted cancer therapeutic research: where do we stand?</article-title><source>Cell Death Dis.</source><volume>7</volume><year>2016</year><object-id pub-id-type="publisher-id">e2058</object-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Bailon-Moscoso</surname><given-names>N.</given-names></name><name><surname>Cevallos-Solorzano</surname><given-names>G.</given-names></name><name><surname>Romero-Benavides</surname><given-names>J.C.</given-names></name><name><surname>Orellana</surname><given-names>M.I.</given-names></name></person-group><article-title>Natural compounds as modulators of cell cycle arrest: application for anticancer chemotherapies</article-title><source>Curr. Genom.</source><volume>18</volume><year>2017</year><fpage>106</fpage><lpage>131</lpage></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>A.S.</given-names><suffix>Jr.</suffix></name></person-group><article-title>The NF-kappa B and I kappa B proteins: new discoveries and insights</article-title><source>Annu. Rev. Immunol.</source><volume>14</volume><year>1996</year><fpage>649</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">8717528</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Bisogno</surname><given-names>F.</given-names></name><name><surname>Mascoti</surname><given-names>L.</given-names></name><name><surname>Sanchez</surname><given-names>C.</given-names></name><name><surname>Garibotto</surname><given-names>F.</given-names></name><name><surname>Giannini</surname><given-names>F.</given-names></name><name><surname>Kurina-Sanz</surname><given-names>M.</given-names></name><name><surname>Enriz</surname><given-names>R.</given-names></name></person-group><article-title>Structure-Antifungal activity relationship of cinnamic acid derivatives</article-title><source>J. Agric. Food Chem.</source><volume>55</volume><year>2007</year><fpage>10635</fpage><lpage>10640</lpage><pub-id pub-id-type="pmid">18038998</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Cargnello</surname><given-names>M.</given-names></name><name><surname>Roux</surname><given-names>P.P.</given-names></name></person-group><article-title>Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases</article-title><source>Microbiol. Mol. Biol. Rev.</source><volume>75</volume><year>2011</year><fpage>50</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">21372320</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>H.Y.</given-names></name><name><surname>Peng</surname><given-names>W.H.</given-names></name><name><surname>Sheu</surname><given-names>M.J.</given-names></name><name><surname>Huang</surname><given-names>G.J.</given-names></name><name><surname>Tseng</surname><given-names>M.C.</given-names></name><name><surname>Lai</surname><given-names>M.T.</given-names></name><name><surname>Ho</surname><given-names>Y.L.</given-names></name><name><surname>Chang</surname><given-names>Y.S.</given-names></name></person-group><article-title>Hepatoprotective and antioxidant effects of ethanol extract from Phellinus merrillii on carbon tetrachloride-induced liver damage</article-title><source>Am. J. Chin. Med.</source><volume>35</volume><year>2007</year><fpage>793</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">17963319</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>F.Y.</given-names></name><name><surname>Li</surname><given-names>Y.Q.</given-names></name></person-group><article-title>The apoptosis effect of hispolon from Phellinus linteus (Berkeley &#x00026; Curtis) Teng on human epidermoid KB cells</article-title><source>J. Ethnopharmacol.</source><volume>105</volume><year>2006</year><fpage>280</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">16563677</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>S.F.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.Q.</given-names></name></person-group><article-title>Hispolon induces apoptosis in human gastric cancer cells through a ROS-mediated mitochondrial pathway</article-title><source>Free Radic. Biol. Med.</source><volume>45</volume><year>2008</year><fpage>60</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">18423410</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.C.</given-names></name><name><surname>Chang</surname><given-names>H.Y.</given-names></name><name><surname>Deng</surname><given-names>J.S.</given-names></name><name><surname>Chen</surname><given-names>J.J.</given-names></name><name><surname>Huang</surname><given-names>S.S.</given-names></name><name><surname>Lin</surname><given-names>I.H.</given-names></name><name><surname>Kuo</surname><given-names>W.L.</given-names></name><name><surname>Chao</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>G.J.</given-names></name></person-group><article-title>Hispolon from Phellinus linteus induces G0/G1 cell cycle arrest and apoptosis in NB4 human leukaemia cells</article-title><source>Am. J. Chin. Med.</source><volume>41</volume><year>2013</year><fpage>1439</fpage><lpage>1457</lpage><pub-id pub-id-type="pmid">24228611</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.S.</given-names></name><name><surname>Lee</surname><given-names>S.M.</given-names></name><name><surname>Lin</surname><given-names>C.C.</given-names></name><name><surname>Liu</surname><given-names>C.Y.</given-names></name></person-group><article-title>Hispolon decreases melanin production and induces apoptosis in melanoma cells through the downregulation of tyrosinase and microphthalmia-associated transcription factor (MITF) expressions and the activation of caspase-3, -8 and -9</article-title><source>Int. J. Mol. Sci.</source><volume>15</volume><year>2014</year><fpage>1201</fpage><lpage>1215</lpage><pub-id pub-id-type="pmid">24445257</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Tan</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name></person-group><article-title>A review: the bioactivities and pharmacological applications of Phellinus linteus</article-title><source>Molecules</source><volume>24</volume><year>2019</year></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Chethna</surname><given-names>P.</given-names></name><name><surname>Iyer</surname><given-names>S.S.</given-names></name><name><surname>Gandhi</surname><given-names>V.V.</given-names></name><name><surname>Kunwar</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>B.G.</given-names></name><name><surname>Barik</surname><given-names>A.</given-names></name><name><surname>Balaji</surname><given-names>N.V.</given-names></name><name><surname>Ramani</surname><given-names>M.V.</given-names></name><name><surname>Subbaraju</surname><given-names>G.V.</given-names></name><name><surname>Priyadarsini</surname><given-names>K.I.</given-names></name></person-group><article-title>Toxicity and antigenotoxic effect of hispolon derivatives: role of structure in modulating cellular redox state and thioredoxin reductase</article-title><source>ACS Omega</source><volume>3</volume><year>2018</year><fpage>5958</fpage><lpage>5970</lpage><pub-id pub-id-type="pmid">30023935</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Chethna</surname><given-names>P.</given-names></name><name><surname>Iyer</surname><given-names>S.S.</given-names></name><name><surname>Gandhi</surname><given-names>V.V.</given-names></name><name><surname>Kunwar</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>B.G.</given-names></name><name><surname>Barik</surname><given-names>A.</given-names></name><name><surname>Balaji</surname><given-names>N.V.</given-names></name><name><surname>Ramani</surname><given-names>M.V.</given-names></name><name><surname>Subbaraju</surname><given-names>G.V.</given-names></name><name><surname>Priyadarsini</surname><given-names>K.I.</given-names></name></person-group><article-title>Toxicity and antigenotoxic effect of hispolon derivatives: role of structure in modulating cellular redox state and thioredoxin reductase</article-title><source>ACS Omega</source><volume>3</volume><year>2018</year><fpage>5958</fpage><lpage>5970</lpage><pub-id pub-id-type="pmid">30023935</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>H.</given-names></name><name><surname>Pandey</surname><given-names>M.</given-names></name><name><surname>Hua</surname><given-names>C.K.</given-names></name><name><surname>Mun</surname><given-names>C.S.</given-names></name><name><surname>Jing</surname><given-names>J.K.</given-names></name><name><surname>Kong</surname><given-names>L.</given-names></name><name><surname>Ern</surname><given-names>L.Y.</given-names></name><name><surname>Ashraf</surname><given-names>N.A.</given-names></name><name><surname>Kit</surname><given-names>S.W.</given-names></name><name><surname>Yee</surname><given-names>T.S.</given-names></name><name><surname>Pichika</surname><given-names>M.R.</given-names></name><name><surname>Gorain</surname><given-names>B.</given-names></name><name><surname>Kesharwani</surname><given-names>P.</given-names></name></person-group><article-title>An update on natural compounds in the remedy of diabetes mellitus: a systematic review</article-title><source>J Tradit Complement Med</source><volume>8</volume><year>2018</year><fpage>361</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">29992107</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Cragg</surname><given-names>G.M.</given-names></name><name><surname>Newman</surname><given-names>D.J.</given-names></name></person-group><article-title>Natural product drug discovery in the next millennium</article-title><source>Pharmaceut. Biol.</source><volume>39</volume><year>2001</year><fpage>8</fpage><lpage>17</lpage></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Cragg</surname><given-names>G.M.</given-names></name><name><surname>Newman</surname><given-names>D.J.</given-names></name></person-group><article-title>Natural products: a continuing source of novel drug leads</article-title><source>Biochim. Biophys. Acta</source><volume>1830</volume><year>2013</year><fpage>3670</fpage><lpage>3695</lpage><pub-id pub-id-type="pmid">23428572</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><article-title>Antivirals and antiviral strategies</article-title><source>Nat. Rev. Microbiol.</source><volume>2</volume><year>2004</year><fpage>704</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">15372081</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Demain</surname><given-names>A.L.</given-names></name><name><surname>Vaishnav</surname><given-names>P.</given-names></name></person-group><article-title>Natural products for cancer chemotherapy</article-title><source>Microb Biotechnol</source><volume>4</volume><year>2011</year><fpage>687</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">21375717</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Dos Santos</surname><given-names>C.N.</given-names></name><name><surname>Menezes</surname><given-names>R.</given-names></name><name><surname>Stewart</surname><given-names>D.</given-names></name></person-group><article-title>Polyphenols as new leads in drug discovery: biological activity and mechanisms</article-title><source>Curr. Pharmaceut. Des.</source><volume>24</volume><year>2018</year><fpage>2041</fpage><lpage>2042</lpage></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Elmore</surname><given-names>S.</given-names></name></person-group><article-title>Apoptosis: a review of programmed cell death</article-title><source>Toxicol. Pathol.</source><volume>35</volume><year>2007</year><fpage>495</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">17562483</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Gaoa</surname><given-names>X.</given-names></name><name><surname>Tangb</surname><given-names>J.</given-names></name><name><surname>Liub</surname><given-names>H.</given-names></name><name><surname>Liub</surname><given-names>L.</given-names></name><name><surname>Chenc</surname><given-names>L.K.a.W.</given-names></name></person-group><article-title>Structure-activity relationship investigation of tertiary amine derivatives of cinnamic acid as acetylcholinesterase and butyrylcholinesterase inhibitors:compared with that of phenylpropionic acid, sorbic acid and hexanoic acid</article-title><source>J. Enzym. Inhib. Med. Chem.</source><volume>33</volume><year>2018</year><fpage>519</fpage><lpage>524</lpage></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Greenwell</surname><given-names>M.</given-names></name><name><surname>Rahman</surname><given-names>P.K.</given-names></name></person-group><article-title>Medicinal plants: their use in anticancer treatment</article-title><source>Int. J. Pharma Sci. Res.</source><volume>6</volume><year>2015</year><fpage>4103</fpage><lpage>4112</lpage></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Grewal</surname><given-names>A.S.</given-names></name><name><surname>Bhardwaj</surname><given-names>S.</given-names></name><name><surname>Pandita</surname><given-names>D.</given-names></name><name><surname>Lather</surname><given-names>V.</given-names></name><name><surname>Sekhon</surname><given-names>B.S.</given-names></name></person-group><article-title>Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases</article-title><source>Mini Rev. Med. Chem.</source><volume>16</volume><year>2016</year><fpage>120</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">26349493</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Grundemann</surname><given-names>C.</given-names></name><name><surname>Arnhold</surname><given-names>M.</given-names></name><name><surname>Meier</surname><given-names>S.</given-names></name><name><surname>Backer</surname><given-names>C.</given-names></name><name><surname>Garcia-Kaufer</surname><given-names>M.</given-names></name><name><surname>Grunewald</surname><given-names>F.</given-names></name><name><surname>Steinborn</surname><given-names>C.</given-names></name><name><surname>Klemd</surname><given-names>A.M.</given-names></name><name><surname>Wille</surname><given-names>R.</given-names></name><name><surname>Huber</surname><given-names>R.</given-names></name><name><surname>Lindequist</surname><given-names>U.</given-names></name></person-group><article-title>Effects of Inonotus hispidus extracts and compounds on human immunocompetent cells</article-title><source>Planta Med.</source><volume>82</volume><year>2016</year><fpage>1359</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">27428885</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>X.</given-names></name></person-group><article-title>Cancer metastases: challenges and opportunities</article-title><source>Acta Pharm. Sin. B</source><volume>5</volume><year>2015</year><fpage>402</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">26579471</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Guerra</surname><given-names>B.</given-names></name><name><surname>Issinger</surname><given-names>O.G.</given-names></name></person-group><article-title>Natural compounds and derivatives as ser/thr protein kinase modulators and inhibitors</article-title><source>Pharmaceuticals</source><volume>12</volume><year>2019</year></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>H.Y.</given-names></name><name><surname>Ho</surname><given-names>Y.C.</given-names></name><name><surname>Hsieh</surname><given-names>M.J.</given-names></name><name><surname>Yang</surname><given-names>S.F.</given-names></name><name><surname>Chuang</surname><given-names>C.Y.</given-names></name><name><surname>Lin</surname><given-names>C.W.</given-names></name><name><surname>Hsin</surname><given-names>C.H.</given-names></name></person-group><article-title>Hispolon suppresses migration and invasion of human nasopharyngeal carcinoma cells by inhibiting the urokinase-plasminogen activator through modulation of the Akt signaling pathway</article-title><source>Environ. Toxicol.</source><volume>32</volume><year>2017</year><fpage>645</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">27037602</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Hoesel</surname><given-names>B.</given-names></name><name><surname>Schmid</surname><given-names>J.A.</given-names></name></person-group><article-title>The complexity of NF-kappaB signaling in inflammation and cancer</article-title><source>Mol. Canc.</source><volume>12</volume><year>2013</year><fpage>86</fpage></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>D.</given-names></name><name><surname>Park</surname><given-names>M.J.</given-names></name><name><surname>Jang</surname><given-names>E.H.</given-names></name><name><surname>Jung</surname><given-names>B.</given-names></name><name><surname>Kim</surname><given-names>N.J.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name></person-group><article-title>Hispolon as an inhibitor of TGF-beta-induced epithelial-mesenchymal transition in human epithelial cancer cells by co-regulation of TGF-beta-Snail/Twist axis</article-title><source>Oncol Lett</source><volume>14</volume><year>2017</year><fpage>4866</fpage><lpage>4872</lpage><pub-id pub-id-type="pmid">29085494</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>P.C.</given-names></name><name><surname>Hsieh</surname><given-names>Y.H.</given-names></name><name><surname>Chow</surname><given-names>J.M.</given-names></name><name><surname>Yang</surname><given-names>S.F.</given-names></name><name><surname>Hsiao</surname><given-names>M.</given-names></name><name><surname>Hua</surname><given-names>K.T.</given-names></name><name><surname>Lin</surname><given-names>C.H.</given-names></name><name><surname>Chen</surname><given-names>H.Y.</given-names></name><name><surname>Chien</surname><given-names>M.H.</given-names></name></person-group><article-title>Hispolon induces apoptosis through JNK1/2-mediated activation of a caspase-8, -9, and -3-dependent pathway in acute myeloid leukemia (AML) cells and inhibits AML xenograft tumor growth in vivo</article-title><source>J. Agric. Food Chem.</source><volume>61</volume><year>2013</year><fpage>10063</fpage><lpage>10073</lpage><pub-id pub-id-type="pmid">24093560</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>M.J.</given-names></name><name><surname>Chien</surname><given-names>S.Y.</given-names></name><name><surname>Chou</surname><given-names>Y.E.</given-names></name><name><surname>Chen</surname><given-names>C.J.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>M.K.</given-names></name></person-group><article-title>Hispolon from Phellinus linteus possesses mediate caspases activation and induces human nasopharyngeal carcinomas cells apoptosis through ERK1/2, JNK1/2 and p38 MAPK pathway</article-title><source>Phytomedicine</source><volume>21</volume><year>2014</year><fpage>1746</fpage><lpage>1752</lpage><pub-id pub-id-type="pmid">25442286</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>M.J.</given-names></name><name><surname>Chien</surname><given-names>S.Y.</given-names></name><name><surname>Chou</surname><given-names>Y.E.</given-names></name><name><surname>Chen</surname><given-names>C.J.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>M.K.</given-names></name></person-group><article-title>Hispolon from Phellinus linteus possesses mediate caspases activation and induces human nasopharyngeal carcinomas cells apoptosis through ERK1/2, JNK1/2 and p38 MAPK pathway Phytomedicine 21 (2014) 1746-1752</article-title><source>Phytomedicine</source><volume>45</volume><year>2018</year><fpage>121</fpage><pub-id pub-id-type="pmid">28040306</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Hsin</surname><given-names>M.C.</given-names></name><name><surname>Hsieh</surname><given-names>Y.H.</given-names></name><name><surname>Wang</surname><given-names>P.H.</given-names></name><name><surname>Ko</surname><given-names>J.L.</given-names></name><name><surname>Hsin</surname><given-names>I.L.</given-names></name><name><surname>Yang</surname><given-names>S.F.</given-names></name></person-group><article-title>Hispolon suppresses metastasis via autophagic degradation of cathepsin S in cervical cancer cells</article-title><source>Cell Death Dis.</source><volume>8</volume><year>2017</year><object-id pub-id-type="publisher-id">e3089</object-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>G.J.</given-names></name><name><surname>Yang</surname><given-names>C.M.</given-names></name><name><surname>Chang</surname><given-names>Y.S.</given-names></name><name><surname>Amagaya</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>H.C.</given-names></name><name><surname>Hou</surname><given-names>W.C.</given-names></name><name><surname>Huang</surname><given-names>S.S.</given-names></name><name><surname>Hu</surname><given-names>M.L.</given-names></name></person-group><article-title>Hispolon suppresses SK-Hep1 human hepatoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen activator through the PI3K/Akt and ERK signaling pathways</article-title><source>J. Agric. Food Chem.</source><volume>58</volume><year>2010</year><fpage>9468</fpage><lpage>9475</lpage><pub-id pub-id-type="pmid">20698552</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>G.J.</given-names></name><name><surname>Hsieh</surname><given-names>W.T.</given-names></name><name><surname>Chang</surname><given-names>H.Y.</given-names></name><name><surname>Huang</surname><given-names>S.S.</given-names></name><name><surname>Lin</surname><given-names>Y.C.</given-names></name><name><surname>Kuo</surname><given-names>Y.H.</given-names></name></person-group><article-title>alpha-Glucosidase and aldose reductase inhibitory activities from the fruiting body of Phellinus merrillii</article-title><source>J. Agric. Food Chem.</source><volume>59</volume><year>2011</year><fpage>5702</fpage><lpage>5706</lpage><pub-id pub-id-type="pmid">21452825</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>G.J.</given-names></name><name><surname>Deng</surname><given-names>J.S.</given-names></name><name><surname>Huang</surname><given-names>S.S.</given-names></name><name><surname>Hu</surname><given-names>M.L.</given-names></name></person-group><article-title>Hispolon induces apoptosis and cell cycle arrest of human hepatocellular carcinoma Hep3B cells by modulating ERK phosphorylation</article-title><source>J. Agric. Food Chem.</source><volume>59</volume><year>2011</year><fpage>7104</fpage><lpage>7113</lpage><pub-id pub-id-type="pmid">21630638</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.Y.</given-names></name><name><surname>Ju</surname><given-names>D.T.</given-names></name><name><surname>Chang</surname><given-names>C.F.</given-names></name><name><surname>Muralidhar Reddy</surname><given-names>P.</given-names></name><name><surname>Velmurugan</surname><given-names>B.K.</given-names></name></person-group><article-title>A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer</article-title><source>Biomedicine</source><volume>7</volume><year>2017</year><fpage>23</fpage><pub-id pub-id-type="pmid">29130448</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Jan</surname><given-names>R.</given-names></name><name><surname>Chaudhry</surname><given-names>G.E.</given-names></name></person-group><article-title>Understanding apoptosis and apoptotic pathways targeted cancer therapeutics</article-title><source>Adv. Pharmaceut. Bull.</source><volume>9</volume><year>2019</year><fpage>205</fpage><lpage>218</lpage></element-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>E.H.</given-names></name><name><surname>Jang</surname><given-names>S.Y.</given-names></name><name><surname>Cho</surname><given-names>I.H.</given-names></name><name><surname>Hong</surname><given-names>D.</given-names></name><name><surname>Jung</surname><given-names>B.</given-names></name><name><surname>Park</surname><given-names>M.J.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name></person-group><article-title>Hispolon inhibits the growth of estrogen receptor positive human breast cancer cells through modulation of estrogen receptor alpha</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>463</volume><year>2015</year><fpage>917</fpage><lpage>922</lpage><pub-id pub-id-type="pmid">26056942</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>M.</given-names></name><name><surname>Persson</surname><given-names>J.L.</given-names></name></person-group><article-title>Cancer therapy: targeting cell cycle regulators</article-title><source>Anticancer Agents Med Chem</source><volume>8</volume><year>2008</year><fpage>723</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">18855574</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>D.A.</given-names></name><name><surname>Hart</surname><given-names>J.</given-names></name><name><surname>Seely</surname><given-names>D.</given-names></name></person-group><article-title>Cost effectiveness of natural health products: a systematic review of randomized clinical trials</article-title><source>Evid Based Complement Alternat Med</source><volume>6</volume><year>2009</year><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">18955290</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M.</given-names></name><name><surname>Maryam</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Mehmood</surname><given-names>T.</given-names></name><name><surname>Ma</surname><given-names>T.</given-names></name></person-group><article-title>Killing cancer with platycodin D through multiple mechanisms</article-title><source>J. Cell Mol. Med.</source><volume>20</volume><year>2016</year><fpage>389</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">26648178</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Khansari</surname><given-names>N.</given-names></name><name><surname>Shakiba</surname><given-names>Y.</given-names></name><name><surname>Mahmoudi</surname><given-names>M.</given-names></name></person-group><article-title>Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer</article-title><source>Recent Pat. Inflamm. Allergy Drug Discov.</source><volume>3</volume><year>2009</year><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">19149749</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Kharroubi</surname><given-names>A.T.</given-names></name><name><surname>Darwish</surname><given-names>H.M.</given-names></name></person-group><article-title>Diabetes mellitus: the epidemic of the century</article-title><source>World J. Diabetes</source><volume>6</volume><year>2015</year><fpage>850</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">26131326</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Choi</surname><given-names>B.Y.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>I.Y.</given-names></name><name><surname>Lee</surname><given-names>B.E.</given-names></name><name><surname>Sohn</surname><given-names>M.</given-names></name><name><surname>Park</surname><given-names>H.J.</given-names></name><name><surname>Suh</surname><given-names>S.W.</given-names></name></person-group><article-title>A water-ethanol extract from the willow bracket mushroom, Phellinus igniarius (higher basidiomycetes), reduces transient cerebral ischemia-induced neuronal death</article-title><source>Int. J. Med. Mushrooms</source><volume>17</volume><year>2015</year><fpage>879</fpage><lpage>889</lpage><pub-id pub-id-type="pmid">26756300</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>Y.C.</given-names></name><name><surname>Park</surname><given-names>B.</given-names></name></person-group><article-title>Hispolon from Phellinus linteus induces apoptosis and sensitizes human cancer cells to the tumor necrosis factor-related apoptosis-inducing ligand through upregulation of death receptors</article-title><source>Oncol. Rep.</source><volume>35</volume><year>2016</year><fpage>1020</fpage><lpage>1026</lpage><pub-id pub-id-type="pmid">26718925</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>I.K.</given-names></name><name><surname>Yun</surname><given-names>B.S.</given-names></name></person-group><article-title>Styrylpyrone-class compounds from medicinal fungi Phellinus and Inonotus spp., and their medicinal importance</article-title><source>J. Antibiot. (Tokyo)</source><volume>64</volume><year>2011</year><fpage>349</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">21304532</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="book" id="sref54"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>P.</given-names></name><name><surname>Paetz</surname><given-names>S.</given-names></name><name><surname>Blings</surname><given-names>M.</given-names></name><name><surname>Hoffmann-L&#x000fc;cke</surname><given-names>P.</given-names></name><name><surname>Riess</surname><given-names>G.E.K.T.</given-names></name></person-group><chapter-title>In: Expression of Multidisciplinary Flavour Science</chapter-title><year>2019</year><publisher-name>Symrise GmbH &#x00026; Co. KG, Flavor &#x00026; Nutrition, Research &#x00026; Innovation</publisher-name><publisher-loc>Holzminden, Germany</publisher-loc><fpage>402</fpage><lpage>405</lpage></element-citation></ref><ref id="bib55"><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>J.B.</given-names></name></person-group><article-title>Viruses and human cancer</article-title><source>Yale J. Biol. Med.</source><volume>79</volume><year>2006</year><fpage>115</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">17940621</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C.J.</given-names></name><name><surname>Lien</surname><given-names>H.M.</given-names></name><name><surname>Chang</surname><given-names>H.Y.</given-names></name><name><surname>Huang</surname><given-names>C.L.</given-names></name><name><surname>Liu</surname><given-names>J.J.</given-names></name><name><surname>Chang</surname><given-names>Y.C.</given-names></name><name><surname>Chen</surname><given-names>C.C.</given-names></name><name><surname>Lai</surname><given-names>C.H.</given-names></name></person-group><article-title>Biological evaluation of Phellinus linteus-fermented broths as anti-inflammatory agents</article-title><source>J. Biosci. Bioeng.</source><volume>118</volume><year>2014</year><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">24503424</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Loreto</surname><given-names>C.</given-names></name><name><surname>La Rocca</surname><given-names>G.</given-names></name><name><surname>Anzalone</surname><given-names>R.</given-names></name><name><surname>Caltabiano</surname><given-names>R.</given-names></name><name><surname>Vespasiani</surname><given-names>G.</given-names></name><name><surname>Castorina</surname><given-names>S.</given-names></name><name><surname>Ralph</surname><given-names>D.J.</given-names></name><name><surname>Cellek</surname><given-names>S.</given-names></name><name><surname>Musumeci</surname><given-names>G.</given-names></name><name><surname>Giunta</surname><given-names>S.</given-names></name><name><surname>Djinovic</surname><given-names>R.</given-names></name><name><surname>Basic</surname><given-names>D.</given-names></name><name><surname>Sansalone</surname><given-names>S.</given-names></name></person-group><article-title>The role of intrinsic pathway in apoptosis activation and progression in Peyronie's disease</article-title><source>BioMed Res. Int.</source><volume>2014</volume><year>2014</year><fpage>616149</fpage><pub-id pub-id-type="pmid">25197653</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>T.L.</given-names></name><name><surname>Huang</surname><given-names>G.J.</given-names></name><name><surname>Lu</surname><given-names>T.J.</given-names></name><name><surname>Wu</surname><given-names>J.B.</given-names></name><name><surname>Wu</surname><given-names>C.H.</given-names></name><name><surname>Yang</surname><given-names>T.C.</given-names></name><name><surname>Iizuka</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>Y.F.</given-names></name></person-group><article-title>Hispolon from Phellinus linteus has antiproliferative effects via MDM2-recruited ERK1/2 activity in breast and bladder cancer cells</article-title><source>Food Chem. Toxicol.</source><volume>47</volume><year>2009</year><fpage>2013</fpage><lpage>2021</lpage><pub-id pub-id-type="pmid">19477214</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Manach</surname><given-names>C.</given-names></name><name><surname>Scalbert</surname><given-names>A.</given-names></name><name><surname>Morand</surname><given-names>C.</given-names></name><name><surname>Remesy</surname><given-names>C.</given-names></name><name><surname>Jimenez</surname><given-names>L.</given-names></name></person-group><article-title>Polyphenols: food sources and bioavailability</article-title><source>Am. J. Clin. Nutr.</source><volume>79</volume><year>2004</year><fpage>727</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">15113710</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Masood</surname><given-names>M.</given-names></name><name><surname>Rasul</surname><given-names>A.</given-names></name><name><surname>Sarfraz</surname><given-names>I.</given-names></name><name><surname>Jabeen</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Hispolon induces apoptosis against prostate DU145 cancer cells via modulation of mitochondrial and STAT3 pathways</article-title><source>Pak. J. Pharm. Sci.</source><volume>32</volume><year>2019</year><fpage>2237</fpage><lpage>2243</lpage><pub-id pub-id-type="pmid">31894049</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Phelligridins</surname><given-names>C.-F.</given-names></name></person-group><article-title>Cytotoxic pyrano[4,3-c][2]benzopyran-1,6-dione and furo[3,2-c]pyran-4-one derivatives from the fungus Phellinus igniarius</article-title><source>J. Nat. Prod.</source><volume>67</volume><year>2004</year><fpage>823</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">15165144</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Napetschnig</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name></person-group><article-title>Molecular basis of NF-kappaB signaling</article-title><source>Annu. Rev. Biophys.</source><volume>42</volume><year>2013</year><fpage>443</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">23495970</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>M.</given-names></name><name><surname>Kumar Panda</surname><given-names>M.</given-names></name><name><surname>Thatoi</surname><given-names>H.</given-names></name></person-group><article-title>Developing Hispolon-based novel anticancer therapeutics against human (NF-kappabeta) using in silico approach of modelling, docking and protein dynamics</article-title><source>J. Biomol. Struct. Dyn.</source><volume>37</volume><year>2019</year><fpage>3947</fpage><lpage>3967</lpage><pub-id pub-id-type="pmid">30295165</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Peluso</surname><given-names>I.</given-names></name><name><surname>Yarla</surname><given-names>N.S.</given-names></name><name><surname>Ambra</surname><given-names>R.</given-names></name><name><surname>Pastore</surname><given-names>G.</given-names></name><name><surname>Perry</surname><given-names>G.</given-names></name></person-group><article-title>MAPK signalling pathway in cancers: olive products as cancer preventive and therapeutic agents</article-title><source>Semin. Canc. Biol.</source><volume>56</volume><year>2019</year><fpage>185</fpage><lpage>195</lpage></element-citation></ref><ref id="bib65"><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Punchard</surname><given-names>N.A.</given-names></name><name><surname>Whelan</surname><given-names>C.J.</given-names></name><name><surname>Adcock</surname><given-names>I.</given-names></name></person-group><source>The Journal of Inflammation, J Inflamm (Lond).</source><volume>1</volume><year>2004</year><fpage>1</fpage></element-citation></ref><ref id="bib66"><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Rasul</surname><given-names>A.</given-names></name><name><surname>Millimouno</surname><given-names>F.M.</given-names></name><name><surname>Ali Eltayb</surname><given-names>W.</given-names></name><name><surname>Ali</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Pinocembrin: a novel natural compound with versatile pharmacological and biological activities</article-title><source>BioMed Res. Int.</source><volume>2013</volume><year>2013</year><fpage>379850</fpage><pub-id pub-id-type="pmid">23984355</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Ravindran</surname><given-names>J.</given-names></name><name><surname>Subbaraju</surname><given-names>G.V.</given-names></name><name><surname>Ramani</surname><given-names>M.V.</given-names></name><name><surname>Sung</surname><given-names>B.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Bisdemethylcurcumin and structurally related hispolon analogues of curcumin exhibit enhanced prooxidant, anti-proliferative and anti-inflammatory activities in vitro</article-title><source>Biochem. Pharmacol.</source><volume>79</volume><year>2010</year><fpage>1658</fpage><lpage>1666</lpage><pub-id pub-id-type="pmid">20138025</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Rossia</surname><given-names>M.</given-names></name><name><surname>Carusoa</surname><given-names>F.</given-names></name><name><surname>Costanzinia</surname><given-names>I.</given-names></name><name><surname>Kloera</surname><given-names>C.</given-names></name><name><surname>Sulovaria</surname><given-names>A.</given-names></name><name><surname>Montic</surname><given-names>E.</given-names></name><name><surname>Gariboldic</surname><given-names>M.</given-names></name><name><surname>Marrasc</surname><given-names>E.</given-names></name><name><surname>Balajid</surname><given-names>N.V.</given-names></name><name><surname>Ramanid</surname><given-names>M.V.</given-names></name><name><surname>Subbaraju</surname><given-names>G.V.</given-names></name></person-group><article-title>X-ray crystal structures, density functional theory and docking on deacetylase enzyme for antiproliferative activity of hispolon derivatives on HCT116 colon cancer</article-title><source>Bioorg. Med. Chem.</source><volume>27</volume><year>2019</year><fpage>3805</fpage><lpage>3812</lpage><pub-id pub-id-type="pmid">31326241</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Safarzadeh</surname><given-names>E.</given-names></name><name><surname>Sandoghchian Shotorbani</surname><given-names>S.</given-names></name><name><surname>Baradaran</surname><given-names>B.</given-names></name></person-group><article-title>Herbal medicine as inducers of apoptosis in cancer treatment</article-title><source>Adv. Pharmaceut. Bull.</source><volume>4</volume><year>2014</year><fpage>421</fpage><lpage>427</lpage></element-citation></ref><ref id="bib70"><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>I.</given-names></name><name><surname>Dynlacht</surname><given-names>B.D.</given-names></name></person-group><article-title>New insights into cyclins, CDKs, and cell cycle control</article-title><source>Semin. Cell Dev. Biol.</source><volume>16</volume><year>2005</year><fpage>311</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">15840440</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name><surname>Sarfraz</surname><given-names>I.</given-names></name><name><surname>Rasul</surname><given-names>A.</given-names></name><name><surname>Jabeen</surname><given-names>F.</given-names></name><name><surname>Younis</surname><given-names>T.</given-names></name><name><surname>Zahoor</surname><given-names>M.K.</given-names></name><name><surname>Arshad</surname><given-names>M.</given-names></name><name><surname>Ali</surname><given-names>M.</given-names></name></person-group><article-title>Fraxinus: A Plant with Versatile Pharmacological and Biological Activities</article-title><source>Evid Based Complement Alternat Med</source><issue>2017</issue><year>2017</year><fpage>4269868</fpage><pub-id pub-id-type="pmid">29279716</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Schirrmacher</surname><given-names>V.</given-names></name></person-group><article-title>From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review)</article-title><source>Int. J. Oncol.</source><volume>54</volume><year>2019</year><fpage>407</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">30570109</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>B.M.</given-names></name><name><surname>Ribnicky</surname><given-names>D.M.</given-names></name><name><surname>Lipsky</surname><given-names>P.E.</given-names></name><name><surname>Raskin</surname><given-names>I.</given-names></name></person-group><article-title>Revisiting the ancient concept of botanical therapeutics</article-title><source>Nat. Chem. Biol.</source><volume>3</volume><year>2007</year><fpage>360</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">17576417</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Schueffler</surname><given-names>A.</given-names></name><name><surname>Anke</surname><given-names>T.</given-names></name></person-group><article-title>Fungal natural products in research and development</article-title><source>Nat. Prod. Rep.</source><volume>31</volume><year>2014</year><fpage>1425</fpage><lpage>1448</lpage><pub-id pub-id-type="pmid">25122538</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Sencanski</surname><given-names>M.</given-names></name><name><surname>Radosevic</surname><given-names>D.</given-names></name><name><surname>Perovic</surname><given-names>V.</given-names></name><name><surname>Gemovic</surname><given-names>B.</given-names></name><name><surname>Stanojevic</surname><given-names>M.</given-names></name><name><surname>Veljkovic</surname><given-names>N.</given-names></name><name><surname>Glisic</surname><given-names>S.</given-names></name></person-group><article-title>Natural products as promising therapeutics for treatment of influenza disease</article-title><source>Curr. Pharmaceut. Des.</source><volume>21</volume><year>2015</year><fpage>5573</fpage><lpage>5588</lpage></element-citation></ref><ref id="bib75"><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Sliva</surname><given-names>D.</given-names></name></person-group><article-title>Medicinal mushroom Phellinus linteus as an alternative cancer therapy</article-title><source>Exp Ther Med</source><volume>1</volume><year>2010</year><fpage>407</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">22993555</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Soares-Silva</surname><given-names>M.</given-names></name><name><surname>Diniz</surname><given-names>F.F.</given-names></name><name><surname>Gomes</surname><given-names>G.N.</given-names></name><name><surname>Bahia</surname><given-names>D.</given-names></name></person-group><article-title>The mitogen-activated protein kinase (MAPK) pathway: role in immune evasion by trypanosomatids</article-title><source>Front. Microbiol.</source><volume>7</volume><year>2016</year><fpage>183</fpage><pub-id pub-id-type="pmid">26941717</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Sostres</surname><given-names>C.</given-names></name><name><surname>Gargallo</surname><given-names>C.J.</given-names></name><name><surname>Arroyo</surname><given-names>M.T.</given-names></name><name><surname>Lanas</surname><given-names>A.</given-names></name></person-group><article-title>Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract</article-title><source>Best Pract. Res. Clin. Gastroenterol.</source><volume>24</volume><year>2010</year><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">20227026</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Suabjakyong</surname><given-names>P.</given-names></name><name><surname>Saiki</surname><given-names>R.</given-names></name><name><surname>Van Griensven</surname><given-names>L.J.</given-names></name><name><surname>Higashi</surname><given-names>K.</given-names></name><name><surname>Nishimura</surname><given-names>K.</given-names></name><name><surname>Igarashi</surname><given-names>K.</given-names></name><name><surname>Toida</surname><given-names>T.</given-names></name></person-group><article-title>Polyphenol extract from Phellinus igniarius protects against acrolein toxicity in vitro and provides protection in a mouse stroke model</article-title><source>PloS One</source><volume>10</volume><year>2015</year><object-id pub-id-type="publisher-id">e0122733</object-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Sulkowska-Ziaja</surname><given-names>K.</given-names></name><name><surname>Muszynska</surname><given-names>B.</given-names></name><name><surname>Konska</surname><given-names>G.</given-names></name></person-group><article-title>Biologically active compounds of fungal origin displaying antitumor activity</article-title><source>Acta Pol. Pharm.</source><volume>62</volume><year>2005</year><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">16161358</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y.S.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>H.P.</given-names></name></person-group><article-title>Hispolon inhibits TPA-induced invasion by reducing MMP-9 expression through the NF-kappaB signaling pathway in MDA-MB-231 human breast cancer cells</article-title><source>Oncol Lett</source><volume>10</volume><year>2015</year><fpage>536</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">26171065</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Toopmuanga</surname><given-names>P.</given-names></name><name><surname>Khamchuma</surname><given-names>C.</given-names></name><name><surname>Punsuvon</surname><given-names>V.</given-names></name></person-group><article-title>Detection and confirmation of hispolon in the mushroom Phellinus linteus</article-title><source>Sci. Asia</source><volume>40</volume><year>2014</year><fpage>141</fpage><lpage>144</lpage></element-citation></ref><ref id="bib82"><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Veeresham</surname><given-names>C.</given-names></name></person-group><article-title>Natural products derived from plants as a source of drugs</article-title><source>"J. Adv. Pharm. Technol. Research"" (JAPTR)"</source><volume>3</volume><year>2012</year><fpage>200</fpage><lpage>201</lpage></element-citation></ref><ref id="bib83"><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>Venkateswarlu</surname><given-names>S.</given-names></name><name><surname>Ramachandra</surname><given-names>M.S.</given-names></name><name><surname>Sethuramu</surname><given-names>K.</given-names></name><name><surname>Subbaraju</surname><given-names>G.V.</given-names></name></person-group><article-title>Synthesis and antioxidant activity of hispolon, a yellow pigment from Inonotus hispidius</article-title><source>ChemInform</source><volume>33</volume><year>2010</year></element-citation></ref><ref id="bib84"><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>F.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>N.</given-names></name><name><surname>Cheng</surname><given-names>F.</given-names></name><name><surname>Deng</surname><given-names>Z.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Zou</surname><given-names>K.</given-names></name></person-group><article-title>Estrogenic and anti-estrogenic activities of hispolon from Phellinus lonicerinus (Bond.) Bond. et sing</article-title><source>Fitoterapia</source><volume>95</volume><year>2014</year><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">24637110</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Simpson</surname><given-names>E.R.</given-names></name><name><surname>Brown</surname><given-names>K.A.</given-names></name></person-group><article-title>p53: protection against tumor growth beyond effects on cell cycle and apoptosis</article-title><source>Can. Res.</source><volume>75</volume><year>2015</year><fpage>5001</fpage><lpage>5007</lpage></element-citation></ref><ref id="bib86"><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>F.</given-names></name><name><surname>Zou</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name></person-group><article-title>Effect of hispolon from Phellinus lonicerinus (agaricomycetes) on estrogen receptors, aromatase, and cyclooxygenase II in MCF-7 breast cancer cells</article-title><source>Int. J. Med. Mushrooms</source><volume>19</volume><year>2017</year><fpage>233</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">28605338</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Weia</surname><given-names>X.</given-names></name><name><surname>Yanga</surname><given-names>Y.</given-names></name><name><surname>Gea</surname><given-names>J.</given-names></name><name><surname>Lina</surname><given-names>X.</given-names></name><name><surname>Liua</surname><given-names>D.</given-names></name><name><surname>Wanga</surname><given-names>S.</given-names></name><name><surname>Zhanga</surname><given-names>J.</given-names></name><name><surname>Zhoua</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name></person-group><article-title>Synthesis, characterization, DNA/BSA interactions and in vitro cytotoxicity study of palladium(II) complexes of hispolon derivatives</article-title><source>J. Inorg. Biochem.</source><volume>202</volume><year>2020</year><fpage>1</fpage><lpage>12</lpage></element-citation></ref><ref id="bib88"><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>R.S.</given-names></name></person-group><article-title>Apoptosis in cancer: from pathogenesis to treatment</article-title><source>J. Exp. Clin. Canc. Res.</source><volume>30</volume><year>2011</year><fpage>87</fpage></element-citation></ref><ref id="bib89"><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Kang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>The anticancer effects of hispolon on lung cancer cells</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>453</volume><year>2014</year><fpage>385</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">25268766</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M.S.</given-names></name><name><surname>Chien</surname><given-names>C.C.</given-names></name><name><surname>Cheng</surname><given-names>K.T.</given-names></name><name><surname>Subbaraju</surname><given-names>G.V.</given-names></name><name><surname>Chen</surname><given-names>Y.C.</given-names></name></person-group><article-title>Hispolon suppresses LPS- or LTA-induced iNOS/NO production and apoptosis in BV-2 microglial cells</article-title><source>Am. J. Chin. Med.</source><volume>45</volume><year>2017</year><fpage>1649</fpage><lpage>1666</lpage><pub-id pub-id-type="pmid">29121802</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>S.</given-names></name><name><surname>Verma</surname><given-names>I.M.</given-names></name></person-group><article-title>NF-kappaB, an active player in human cancers</article-title><source>Cancer Immunol Res</source><volume>2</volume><year>2014</year><fpage>823</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">25187272</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D.P.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Meng</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.J.</given-names></name><name><surname>Li</surname><given-names>H.B.</given-names></name></person-group><article-title>Natural antioxidants in foods and medicinal plants: extraction, assessment and resources</article-title><source>Int. J. Mol. Sci.</source><volume>18</volume><year>2017</year></element-citation></ref><ref id="bib93"><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L.Y.</given-names></name><name><surname>Shen</surname><given-names>S.C.</given-names></name><name><surname>Cheng</surname><given-names>K.T.</given-names></name><name><surname>Subbaraju</surname><given-names>G.V.</given-names></name><name><surname>Chien</surname><given-names>C.C.</given-names></name><name><surname>Chen</surname><given-names>Y.C.</given-names></name></person-group><article-title>Hispolon inhibition of inflammatory apoptosis through reduction of iNOS/NO production via HO-1 induction in macrophages</article-title><source>J. Ethnopharmacol.</source><volume>156</volume><year>2014</year><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">25128739</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Nie</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>X.</given-names></name></person-group><article-title>Targeting PI3K in cancer: mechanisms and advances in clinical trials</article-title><source>Mol. Canc.</source><volume>18</volume><year>2019</year><fpage>26</fpage></element-citation></ref><ref id="bib95"><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>B.</given-names></name><name><surname>Fuchs</surname><given-names>B.C.</given-names></name><name><surname>Medarova</surname><given-names>Z.</given-names></name></person-group><article-title>New directions in the study and treatment of metastatic cancer</article-title><source>Front Oncol</source><volume>8</volume><year>2018</year><fpage>258</fpage><pub-id pub-id-type="pmid">30042926</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name><surname>Yun</surname><given-names>J.M.</given-names></name><name><surname>Min</surname><given-names>K.J.</given-names></name><name><surname>Kwon</surname><given-names>T.K.</given-names></name></person-group><article-title>Involvement of up-regulation of death receptors and bim in hispolon-mediated TNF-related apoptosis-inducing ligand sensitization in human renal carcinoma</article-title><source>J Cancer Prev</source><volume>24</volume><year>2019</year><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">31624721</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.J.</given-names></name><name><surname>Gan</surname><given-names>R.Y.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>A.N.</given-names></name><name><surname>Xu</surname><given-names>D.P.</given-names></name><name><surname>Li</surname><given-names>H.B.</given-names></name></person-group><article-title>Antioxidant phytochemicals for the prevention and treatment of chronic diseases</article-title><source>Molecules</source><volume>20</volume><year>2015</year><fpage>21138</fpage><lpage>21156</lpage><pub-id pub-id-type="pmid">26633317</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>Y.S.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Lv</surname><given-names>L.X.</given-names></name><name><surname>Li</surname><given-names>Y.Q.</given-names></name></person-group><article-title>Hispolon inhibits breast cancer cell migration by reversal of epithelial-to-mesenchymal transition via suppressing the ROS/ERK/Slug/E-cadherin pathway</article-title><source>Oncol. Rep.</source><volume>35</volume><year>2016</year><fpage>896</fpage><lpage>904</lpage><pub-id pub-id-type="pmid">26718128</pub-id></element-citation></ref><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Miao</surname><given-names>F.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name></person-group><article-title>Bioactivity and structure-activity relationship of cinnamic acid esters and their derivatives as potential antifungal agents for plant protection</article-title><source>PloS One</source><volume>12</volume><year>2017</year><fpage>176189</fpage></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgement</title><p>This study was supported by <funding-source id="gs2">NRPU Research</funding-source> Grants (8381/Punjab/NRPU/R&#x00026;D/HEC/2017, 8382/Punjab/NRPU/R&#x00026;D/HEC/2017) and <funding-source id="gs3">ISESCO</funding-source> Research Grant (No. 3620).</p></ack></back></article>